Esperion Therapeutics ESPR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $80.1M+23.2% | $168.45M+144% | $87.31M+69.1% | $82.39M+11.6% | $65M-52.8% | ||
| $8.99M-28.4% | $13.93M+26.9% | $14.13M+35.9% | $7.24M-36.8% | $12.56M-6.3% | ||
| $43.12M+0.3% | $41.43M+12.2% | $41.85M+4.7% | $39.51M-10.6% | $43M+2.4% | ||
| $86.69M-0.5% | $83.21M+13.2% | $97.27M+43.8% | $75.29M+5.7% | $87.09M+33.0% | ||
| $86.69M-0.5% | $83.21M+13.2% | $97.27M+43.8% | $75.29M+5.7% | $87.09M+33.0% | ||
| —— | $32.31M+88.4% | $32.31M+88.4% | $32.31M+88.4% | $32.31M+88.4% | ||
| -$6.58M+70.2% | $85.23M— | -$9.96M+37.9% | $7.1M+175% | -$22.1M-131% | ||
| -8.2%+25.8pp | 50.6%+50.6pp | -11.4%+19.6pp | 8.6%+5.1pp | -34%-86.5pp | ||
| $19.8M+1.9% | $22.64M+37.8% | $22.05M+46.2% | $20.49M+49.3% | $19.43M+38.6% | ||
| $1.18M+10.4% | $1.08M-10.9% | $677K-57.3% | $666K-72.9% | $1.07M-61.4% | ||
| —— | -$5.21M+59.7% | -$5.21M+59.7% | -$5.21M+59.7% | -$5.21M+59.7% | ||
| —— | $460.25K— | $460.25K— | $460.25K— | $460.25K— | ||
| -$25.2M+37.7% | —— | -$31.33M-6.1% | -$12.73M+79.5% | -$40.46M-166% | ||
| -31.5%+30.8pp | —— | -35.9%+21.3pp | -15.4%+68.4pp | -62.2%-107pp | ||
| -$0.10+52.4% | —— | -$0.16-6.7% | -$0.06+81.8% | -$0.21-162% | ||
| -$0.10+52.4% | —— | -$0.16-6.7% | -$0.06+81.8% | -$0.21-158% | ||
| 251.4M+28.2% | 207.9M+11.0% | 200.7M+3.0% | 197.5M+4.6% | 196.1M+3.4% | ||
| 251.4M+28.2% | 207.9M+11.0% | 200.7M+3.0% | 197.5M+4.6% | 196.1M+15.9% | ||
| -$25.2M+37.7% | —— | -$31.33M-6.1% | -$12.73M+79.5% | -$40.46M-166% | ||
| $1.18M+10.4% | $1.08M-10.9% | $677K-57.3% | $666K-72.9% | $1.07M-61.4% | ||
| $8.99M-28.4% | $13.93M+26.9% | $14.13M+35.9% | $7.24M-36.8% | $12.56M-6.3% | ||
| $80.1M+23.2% | $168.45M+144% | $87.31M+69.1% | $82.39M+11.6% | $65M-52.8% | ||
| -$6.58M+70.2% | $85.23M— | -$9.96M+37.9% | $7.1M+175% | -$22.1M-131% | ||
| -$6.55M+70.3% | $85.26M+315,674% | -$9.93M+37.9% | $7.12M+175% | -$22.07M-131% | ||
| -$6.55M+70.3% | $85.26M+315,674% | -$9.93M+37.9% | $7.12M+175% | -$22.07M-131% | ||
| -8.2%+25.8pp | 50.6%+50.6pp | -11.4%+19.6pp | 8.6%+5.1pp | -34%-86.4pp | ||
| -$6.58M+70.2% | $85.23M— | -$9.96M+37.9% | $7.1M+175% | -$22.1M-131% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Esperion Therapeutics's revenue?
- Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.
- Is Esperion Therapeutics profitable?
- Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.
- What is Esperion Therapeutics's earnings per share?
- Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.
- Where does Esperion Therapeutics's income statement data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
